• Respiratory and thoracic cancers

Portrazza Generic Name & Formulations

General Description

Necitumumab 800mg/50mL; soln for IV infusion after dilution; preservative-free.

Pharmacological Class

Human epidermal growth factor receptor (EGFR) inhibitor.

How Supplied

Single-use vial—1


Generic Availability


Portrazza Indications


In combination with gemcitabine and cisplatin, for first-line treatment of metastatic squamous non-small cell lung cancer.

Limitations of Use

Not for treatment of non-squamous non-small cell lung cancer.

Portrazza Dosage and Administration


Give by IV infusion over 60 mins prior to gemcitabine and cisplatin infusion. 800mg on Days 1 and 8 of each 3-week cycle; continue until disease progression or unacceptable toxicity. May premedicate with diphenhydramine HCl (or equivalent) if previously experienced a Grade 1/2 infusion-related reaction. Dose modifications: see full labeling.


Not established.

Portrazza Contraindications

Not Applicable

Portrazza Boxed Warnings

Boxed Warning

Cardiopulmonary arrest. Hypomagnesemia.

Portrazza Warnings/Precautions


Risk of cardiopulmonary arrest and/or sudden death, hypomagnesemia. History of coronary artery disease, CHF, or arrhythmias. Monitor serum electrolytes (eg, magnesium, potassium, calcium) prior to each infusion during therapy and for at least 8 weeks after last dose; withhold for Grade 3/4 electrolyte abnormalities and may resume once improved to Grade ≤2. Replete electrolytes as medically appropriate. Discontinue if serious or life-threatening venous/arterial thromboembolic events or infusion-related reactions occur. Discontinue if Grade 4 skin reactions or Grade 3 skin induration/fibrosis occurs. Limit sun exposure. Embryo-fetal toxicity. Pregnancy; avoid. Use effective contraception during treatment and for 3 months after last dose. Nursing mothers: not recommended (during therapy and for 3 months after last dose).

Portrazza Pharmacokinetics

See Literature

Portrazza Interactions

Portrazza Adverse Reactions

Adverse Reactions

Rash, dermatitis acneiform, vomiting, diarrhea, thromboembolic events, hypomagnesemia, hypocalcemia, hypokalemia; cardiopulmonary arrest, dermatologic toxicities, infusion reactions.

Portrazza Clinical Trials

See Literature

Portrazza Note

Not Applicable

Portrazza Patient Counseling

See Literature